EAGAN, Minn.--(BUSINESS WIRE)--Imprime PGG™ may increase the efficacy of Erbitux® for the treatment of non-small cell lung cancer and potentially other cancers that express epidermal growth factor receptor (EGFR) on their cell surface, according to new preclinical research published in Cancer Research, a journal of the American Association for Cancer Research.
